New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
October 29, 2009
07:13 EDTCRIS
theflyonthewall.com: Curis sees FY09 R&D expenses of $9M-$11M
The company sees general and administrative expenses of $8M-$9M and expects to end 2009 with cash, cash equivalents and marketable securities of $21M-$24M. :theflyonthewall.com



News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.
There are 8 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2012
10:01 EDTCRIS
theflyonthewall.com: On The Fly: Analyst Initiation Summary

Subscribe for More Information
:theflyonthewall.com

February 9, 2012
16:23 EDTCRIS
theflyonthewall.com: Curis initiated with an Overweight at Piper Jaffray

Subscribe for More Information
:theflyonthewall.com

February 8, 2012
07:05 EDTCRIS
theflyonthewall.com: Curis reports Q4 EPS 7c vs. consensus 6c

Subscribe for More Information
:theflyonthewall.com

January 31, 2012
09:13 EDTCRIS
theflyonthewall.com: Curis price target raised to $7 from $5 at Summer Street
Summer Street raised its price target for Curis shares after Erivedge received FDA approval and reiterates a Buy rating on the stock. :theflyonthewall.com
07:21 EDTCRIS
theflyonthewall.com: Curis target raised to $7.50 from $6 at Oppenheimer

Subscribe for More Information
:theflyonthewall.com

January 30, 2012
15:51 EDTCRIS
theflyonthewall.com: Biotech Industry Organization to host a conference

Subscribe for More Information
:theflyonthewall.com
11:30 EDTCRIS
theflyonthewall.com: Curis confirms FDA approval for Erivedge
Curis (CRIS) announced that Erivedge capsule was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first and only FDA-approved medicine for people with advanced forms of the most common skin cancer. It is being developed and will be commercialized by Roche (RHHBY) and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis earned a $10M milestone payment from Genentech as a result of the FDA's approval of Erivedge in this indication and is also entitled to receive royalties on future sales of the product.   :theflyonthewall.com
11:23 EDTCRIS
theflyonthewall.com: Roche unit confirms FDA approval for Erivedge, jointly developed with Curis
Genentech, a member of the Roche Group (RHHBY), announced that Erivedge capsule was approved by the U.S. Food and Drug Administration for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. Roche and Genentech are also evaluating Erivedge in a Phase II trial in people with operable forms of BCC. Roche is developing Erivedge under a collaboration agreement with Curis, Inc. (CRIS) Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialization of Erivedge. :theflyonthewall.com